ClinicalTrials.gg
RecruitingNCT05292794Updated May 28, 2026

Use of CereGate Therapy for Freezing of Gait in PD

An interventional study of CereGate Software; BSN cDBS Programmer; BSN Burst Programmer in Parkinson Disease, Freezing of Gait and Deep Brain Stimulation, sponsored by CereGate Inc.. Recruiting at 7 sites in United States. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by CereGate Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.

Planned enrollment
550th of 1,257
41 · median 36
Started
2022
with 104 others
No phase
586 of 1,650
147 open now
Primary completion
2027-06
later than 175 of 384 live
Registered
1,235th of 1,650
by date

Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 550th largest by planned enrollment of the 1,257 interventional ones that give a count, is one of 105 that started in 2022, is one of 586 with no phase, reaches primary completion later than 175 of the 384 other live ones, and was the 1,235th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

300 more — sign in →

All 305 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,650 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed with Parkinson's Disease.

Read the detailed description

This is a multi-center, controlled, study in which participants diagnosed with Parkinson's Disease (PD) and previously implanted with a subthalamic nucleus deep brain stimulation (STN-DBS) System will be assessed prior to initiation of CereGate (CG) therapy, and during CereGate therapy. No randomization will occur in this study.

Participants will complete a total of five study visits (2 Screening Visits, Initiation Visit, day 60 follow-up and day 61 follow-up). The expected duration of participation in the clinical study is up to 104 days for each subject.

Up to 41 participants diagnosed with PD previously implanted with a compatible STN-DBS System will be enrolled at up to eight (8) sites in the United States. A maximum of 15 subjects may be enrolled at any site.

More information about the study can be found at www.fog-study.com.

03

Conditions studied

  • Parkinson Disease
  • Freezing of Gait
  • Deep Brain Stimulation

Keywords

  • Parkinson Disease
  • Parkinson's Disease
  • Freezing of Gait
  • Freezing of Gait Symptoms in Parkinson Disease
  • Gait Disorders
  • Gait Disorders, Neurologic
  • Gait Disorder, Sensorimotor
  • Motor Disorder
  • Gait Impairment
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has an implanted STN-DBS system with Boston Scientific Gevia™ or Genus™ R16 IPG connected to any brand lead or extension that have been approved by the FDA to be used with Gevia or Genus IPGs.
  2. Participant is receiving treatment with carbidopa/levodopa, and/or with a dopamine agonist at the optimal doses as determined by a movement disorders neurologist.
  3. DBS optimized with documented improvement in motor signs (UPDRSIII) from DBS

Exclusion criteria

Exclusion Criteria:

  1. Participant is unable to understand the study requirements and the treatment procedures, or unwilling / unable to provide written before any study-specific tests or procedures are performed.
  2. Participant is unwilling or unable to comply with visit schedule and study related procedures.
  3. Participant's medication regimen has not been stable for at least 28 days prior to CG initiation.
  4. Participant's DBS stimulation settings have not been stable for at least 28 days prior to CG initiation.
  5. Participant is less than 21 years of age or older than 80 years of age.
  6. Participant is a female who is breastfeeding or of with a positive urine pregnancy test or not using adequate as determined by the study investigator.
  7. Participant has a terminal illness with of \< 1 year.
  8. Participant has history of recurrent or unprovoked seizures.
  9. Participant currently diagnosed with drug or alcohol abuse, per criteria.
  10. Participant is in a very advanced stage of Parkinson's disease defined as: (i) Stage 5 as classified by the Hoehn and Yahr scale on medication and DBS (non-ambulatory) or (ii) participant requires an assistive device to perform the TBC OFF-meds /ON-DBS at the time of enrollment.
  11. Participant has a condition that makes walking difficult or could interfere with the study procedures or confound the evaluation of the study data, including musculoskeletal issues, peripheral neuropathies, hip/knee prostheses, or any visual or anatomical abnormality that affects their walking.
  12. Participant has disabling dyskinesias.
  13. Participant has a history of suicide attempt or current active suicidal ideation as determined by a positive response to Items 2-5 of suicide ideation sub-scale of the Columbia Suicide Severity Rating Scale (CSSRS).
  14. Participant, at the time of enrollment, fails the subthalamic nucleus (STN) stimulation challenge test (subject must perceive distinct bilateral sensations).
  15. Participant has less than 8% arrhythmicity as measured in the Turning and Barrier Course Figures of 8 (TBC-F8) pre-CG therapy (ON Medications/ON DBS /OFF CG).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (estimated)

Study arms

  • Experimental
    PD Patients treated with CereGate Software

    This singular arm contains participants diagnosed with Parkinson's Disease (PD) and previously implanted with a subthalamic nucleus deep brain stimulation (STN-DBS) System. Participants will use the CereGate software for 60(+/-8) days on demand.

    Device: CereGate Software; BSN cDBS Programmer; BSN Burst Programmer

Interventions

  • DeviceCereGate Software; BSN cDBS Programmer; BSN Burst Programmer

    CereGate's objective is to, with a single DBS system implanted in the standard STN location for PD: (i) deliver conventional tonic DBS stimulation of STN-to mitigate dopamine-responsive symptoms; and concurrently (ii) deliver bursting DBS-induced "cueing" stimulation-to mitigate FOG. The sole function of CereGate Software is to guide the clinician through a systematic investigation of the stimulation parameter space to thereby configure / tune CereGate Therapy for each participant. CereGate Software proposes parameters for the clinician to evaluate and assists in documenting the response. It does not send commands to, nor control the output of, the DBS System.

06

What researchers measure

Primary outcomes

  1. Primary Efficacy Objective

    The primary objective of this study is to determine whether adjunctive use of CereGate therapy reduces Freezing of Gait in participants diagnosed with Parkinson's Disease in the ON-MEDS/ON-DBS state. The primary efficacy endpoint for this study is the mean percent change in excess arrhythmicity during Turning and Barriers Course Figures of 8 (TBC-F8) while ON-med/ON-DBS, pre-CG therapy to post-CG Therapy follow-up. The Opal wearable inertial measurement sensor (APDM Inc., Portland, OR) will be used to capture kinemetric data, from which the arrhythmicity will be extracted. Excess arrhythmicity will be calculated by subtracting the "normal" arrhythmicity (during TBC-F8 in age-matched controls).

    Time frame: Pre-CG therapy to post-CG-therapy follow-up Day 60 Visit (Day 60 ± 8)

Secondary outcomes

  1. Secondary Efficacy Endpoint

    The secondary objective of this study is to determine whether adjunctive use of CereGate therapy reduces FOG in participants diagnosed with PD as measured by mean percent change in excess arrhythmicity in the OFF-med/ON-DBS state.

    Time frame: Pre-CG therapy to post-CG-therapy follow-up Day 61 Visit (Day60 Visit +1-8d).

Other outcomes

  1. Safety Endpoints

    Safety endpoints for this study will include the following by interventional condition (i.e., CereGate therapy ON or OFF): Proportion of participants who experience one or more stimulation-related serious adverse events (SAEs) Proportion of participants who experience any stimulation related adverse event Proportion of participants who experience each unique type of adverse event

    Time frame: From 1st Screening Visit through Day 61 (Day 60 Visit +1-8d) follow-up visit.

07

Study locations

7 of 7 sites recruiting
  • Kaiser Permanente, KPNC Comprehensive Movement Disorders Program
    Redwood City, California 94063, United States
    Recruiting
    • Elena Call, MD · Contactelena.call@kp.org · 650-464-6321
    • Elena Call, MD · Principal investigator
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
    Recruiting
  • University of Miami
    Miami, Florida 33136, United States
    Recruiting
    • Ihtsham Haq, MD · Contactihaq@med.miami.edu · 305-243-6732
    • Lissette Perez · Contactlperez4@miami.edu · 305-243-2172
    • Ihtsham Haq, MD · Principal investigator
    • Corneliu Luca, MD · Sub investigator
    • Taylor Peabody, MD · Sub investigator
  • Northwestern University
    Chicago, Illinois 60611, United States
    Recruiting
    • Neil Shetty, MD · ContactNeil.shetty@nm.org · 312-695-7950
    • Neil Shetty, MD · Principal investigator
    • Joshua Rosenow, MD · Sub investigator
    • Jessica Karl, PhD, PA-C · Sub investigator
  • Wake Forest University
    Winston-Salem, North Carolina 27157, United States
    Recruiting
    • Tonya Woosley, CRC · Contacttwoosley@wakehealth.edu · 336-716-9520
    • Deepal Shah-Zamora, MD · Principal investigator
    • Ha Green, PA · Sub investigator
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Recruiting
  • University of Washington
    Seattle, Washington 98195, United States
    Recruiting
    • Sarah Simon · Contactssimon3@uw.edu · 206-221-2132
    • Yi-Han (Anny) Lin, MD · Principal investigator
    • John Sanderson, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Jun 2027, 62 months after the start.

Of 76 industry-sponsored interventional studies with no phase under Parkinson Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's planned 62 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2022
First posted
Mar 23, 2022
StartActual
Apr 18, 2022
Primary completionEst.
Jun 2027
CompletionEst.
Jul 2027
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05292794
Lead sponsor
CereGate Inc.
Responsible party
Sponsor
First posted
Mar 23, 2022
Start date
Apr 18, 2022
Primary completion
Jun 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
May 28, 2026

Study contacts

Kathleen Kmiecik
Contact
kathleen@ceregate.com
330-241-9098
Kathleen Kmiecik
study chair · CereGate Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion